Eurizon Capital SGR S.p.A. Invests $1.70 Million in Solventum Corporation $SOLV

Eurizon Capital SGR S.p.A. acquired a new position in Solventum Corporation (NYSE:SOLV) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 21,475 shares of the company’s stock, valued at approximately $1,703,000.

Several other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in Solventum by 5.3% during the third quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock valued at $1,249,847,000 after acquiring an additional 867,837 shares in the last quarter. Independent Franchise Partners LLP grew its stake in Solventum by 27.2% during the third quarter. Independent Franchise Partners LLP now owns 12,899,240 shares of the company’s stock valued at $941,645,000 after acquiring an additional 2,758,174 shares in the last quarter. State Street Corp grew its stake in Solventum by 1.8% during the third quarter. State Street Corp now owns 6,220,271 shares of the company’s stock valued at $454,080,000 after acquiring an additional 112,261 shares in the last quarter. Davis Selected Advisers grew its stake in Solventum by 12.7% during the fourth quarter. Davis Selected Advisers now owns 6,220,072 shares of the company’s stock valued at $492,880,000 after acquiring an additional 702,461 shares in the last quarter. Finally, Boston Partners grew its stake in Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after acquiring an additional 959,543 shares in the last quarter.

Insider Buying and Selling

In other Solventum news, Director Amy Mcbride Wendell acquired 1,475 shares of the stock in a transaction on Tuesday, March 10th. The stock was acquired at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the transaction, the director directly owned 5,039 shares of the company’s stock, valued at $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.24% of the stock is owned by company insiders.

Solventum Price Performance

SOLV stock opened at $76.40 on Wednesday. Solventum Corporation has a 52 week low of $62.38 and a 52 week high of $88.20. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. The company has a fifty day simple moving average of $69.75 and a two-hundred day simple moving average of $75.08. The firm has a market capitalization of $13.23 billion, a P/E ratio of 9.36, a price-to-earnings-growth ratio of 1.17 and a beta of 0.69.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The business had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. During the same quarter last year, the business earned $1.34 earnings per share. Solventum’s quarterly revenue was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Analysts anticipate that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SOLV has been the subject of several research analyst reports. BTIG Research reaffirmed a “buy” rating and set a $89.00 target price on shares of Solventum in a research note on Wednesday, May 6th. Piper Sandler cut their target price on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Wedbush initiated coverage on shares of Solventum in a research note on Friday, May 15th. They set an “outperform” rating and a $94.00 target price for the company. Wall Street Zen cut shares of Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Finally, KeyCorp raised their target price on shares of Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Eight research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Solventum has an average rating of “Moderate Buy” and a consensus target price of $84.25.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.